secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2026-02-13T23:59:59+00:00
Accession:  0001213900-26-015894
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology reports first revenue of $3.9M from LYMPHIR launch; net loss narrows to $5.5M
--------------------------------------------------------------------------------

- Revenue of $3.9M for Q1 FY2026 ended Dec 31, 2025, first reported sales following December 2025 commercial launch of LYMPHIR.
- Net loss of $5.5M ($0.06 per share) improved from $6.7M loss ($0.09) in prior-year period.
- Cash and equivalents $7.3M as of Dec 31, 2025; raised net proceeds of ~$15.1M via December 2025 registered offering.
- LYMPHIR (denileukin diftitox-cxdl) launched for relapsed/refractory Stage I-III cutaneous T-cell lymphoma; patient initiations underway at leading U.S. cancer centers.
- AI-enabled commercial platform deployed; international access advanced through regional distribution partners in Europe and Middle East.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390026015894/0001213900-26-015894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390026015894/ea0276947-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-015894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer